Potential Role of Probiotics in Ameliorating Psoriasis by Modulating Gut Microbiota in Imiquimod-Induced Psoriasis-Like Mice

Liu, Wenwei; Deng, Yadan; Fang, Zhifeng; Zhai, Qixiao; Cui, Shumao; Zhao, Jianxin; Zhang, Hao

doi:10.3390/nu13062010

Cited by 38 publications

(37 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In imiquimod-induced psoriasis-like mice, the supplementation with probiotics for two weeks resulted in great relief from psoriasis-like pathological characteristics [ 96 ]. More precisely, Bifidobacterium adolescentis CCFM667, B .…”

Section: Gut Microbiome-targeted Therapies For Psoriasismentioning

confidence: 99%

Gut Microbiota in Psoriasis

et al. 2022

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease with autoimmune pathogenic characteristics and is caused by chronic inflammation, which results in uncontrolled keratinocyte growth and defective differentiation. The link between the gut microbiota and immune system regulation opened a novel angle to understand the pathogenesis of many chronic multifactorial diseases, including psoriasis. Current evidence suggests that modulation of the gut microbiota, both through dietary approaches and through supplementation with probiotics and prebiotics, could represent a novel therapeutic approach. The present work aims to highlight the latest scientific evidence regarding the microbiome alterations of psoriatic patients, as well as state of the art insights in terms of microbiome-targeted therapies as promising preventive and therapeutic tools for psoriasis.

show abstract

Section: Gut Microbiome-targeted Therapies For Psoriasismentioning

confidence: 99%

Gut Microbiota in Psoriasis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…B. adolescentis CCFM667, B. breve CCFM1078, Lacticaseibacillus paracasei CCFM1074, and Limosilactobacillus reuteri CCFM1132 ameliorated psoriasis-like pathological characteristics and suppressed the release of IL-23/T helper cell 17 (Th17) axis-related inflammatory cytokines. On the contrary, B. animalis CCFM1148, L. paracasei CCFM1147 and L. reuteri CCFM1040 neither alleviated the pathological characteristics nor reduced the levels of inflammatory cytokines [99]. Ogawa et al showed that administering Leuconostoc mesenteroides NTM048 to imiquimod-induced mice suppressed erythema, scaling, upregulated IL-17 production, increased the levels of plasma deoxycholic acid and altered the faecal microbiota composition.…”

Section: Psoriasismentioning

confidence: 99%

Microbiome Modulation as a Therapeutic Approach in Chronic Skin Diseases

et al. 2021

View full text Add to dashboard Cite

There is a growing quantity of evidence on how skin and gut microbiome composition impacts the course of various dermatological diseases. The strategies involving the modulation of bacterial composition are increasingly in the focus of research attention. The aim of the present review was to analyze the literature available in PubMed (MEDLINE) and EMBASE databases on the topic of microbiome modulation in skin diseases. The effects and possible mechanisms of action of probiotics, prebiotics and synbiotics in dermatological conditions including atopic dermatitis (AD), psoriasis, chronic ulcers, seborrheic dermatitis, burns and acne were analyzed. Due to the very limited number of studies available regarding the topic of microbiome modulation in all skin diseases except for AD, the authors decided to also include case reports and original studies concerning oral administration and topical application of the pro-, pre- and synbiotics in the final analysis. The evaluated studies mostly reported significant health benefits to the patients or show promising results in animal or ex vivo studies. However, due to a limited amount of research and unambiguous results, the topic of microbiome modulation as a therapeutic approach in skin diseases still warrants further investigation.

show abstract

“…For instance, oral administration with L. reuteri CCFM1132, but not L. reuteri CCFM1040, has been shown to reduce the production of IL-23/Th17 axis-associated cytokines in a murine psoriasis-like model. 48 Newborn rats fed with formula supplemented with L. reuteri DSM 17938, but not L. reuteri ATCC PTA 4659, showed diminished intestinal TNFα, IL-1β and IFN-γ production compared to the rats fed with formula alone. 49 Another study has shown that oral gavage with L. reuteri ATCC PTA 4659 significantly diminished colonic IL-1β and IL-6, but not TNFα, production in a murine colitis model.…”

Section: Discussionmentioning

confidence: 93%

Gut commensal Limosilactobacillus reuteri induces atypical memory-like phenotype in human dendritic cells in vitro

et al. 2022

View full text Add to dashboard Cite

Memory-like responses in innate immune cells confer nonspecific protection against secondary exposures. A number of microbial agents have been found to induce enhanced or diminished recall responses in innate cells, however, studies investigating the ability of probiotic bacteria to trigger such effects are lacking. Here, we show that priming of human monocytes with a secretome from the gut probiotic bacterium Limosilactobacillus ( L .) reuteri induces a mixed secondary response phenotype in monocyte-derived dendritic cells (mo-DCs), with a strong IL-6 and IL-1β response but low TNFα, IL-23 and IL-27 secretion. Instead, blood DC priming with L. reuteri -secretome resembles a tolerant state upon secondary exposure. A similar pattern was found in conventional and gut-like (retinoic acid exposed) DCs, although retinoic acid hampered TNFα and IL-6 production and enrichment of histone modifications in L. reuteri -secretome primed mo-DC cultures. Further, we show that the memory-like phenotype of mo-DCs, induced by priming stimuli, is important for subsequent T helper (Th) cell differentiation pathways and might determine the inflammatory nature of Th cells. We also show enhanced recall responses characterized by robust inflammatory cytokines and lactate production in the gut-like mo-DCs derived from β-glucan primed monocytes. Such responses were accompanied with enriched histone modifications at the promoter of genes associated with a trained phenotype in myeloid cells. Altogether, we demonstrate that a gut commensal-derived secretome prompts recall responses in human DCs which differ from that induced by classical training agents such as β-glucan. Our results could be beneficial for future therapeutic interventions where T cell responses are needed to be modulated.

show abstract

Potential Role of Probiotics in Ameliorating Psoriasis by Modulating Gut Microbiota in Imiquimod-Induced Psoriasis-Like Mice

Cited by 38 publications

References 49 publications

Gut Microbiota in Psoriasis

Gut Microbiota in Psoriasis

Microbiome Modulation as a Therapeutic Approach in Chronic Skin Diseases

Gut commensal Limosilactobacillus reuteri induces atypical memory-like phenotype in human dendritic cells in vitro

Contact Info

Product

Resources

About